Document Detail


Two-year course of subfoveal pigment epithelial detachment in eyes with age-related macular degeneration and visual acuity better than 20/40.
MedLine Citation:
PMID:  22508168     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To investigate the course of subfoveal pigment epithelial detachments (PEDs) in eyes with age-related macular degeneration (AMD) and best-corrected visual acuity (BCVA) ≥20/40.
METHODS: Thirty-seven eyes of 35 patients with a subfoveal PED were divided into an avascular PED group (n = 11), a vascularized PED group due to polypoidal choroidal vasculopathy (PCV, n = 14) and an occult choroidal neovascularization (CNV) group (n = 12). Intravitreal bevacizumab or ranibizumab was given as needed. The BCVA, central foveal thickness, PED thickness, and lesion size were measured at baseline and at 2 years after the initial examination.
RESULTS: The BCVA did not change significantly in the avascular group, decreased from 0.06 ± 0.11 to 0.23 ± 0.15 logMAR units in the PCV group and from 0.12 ± 0.12 to 0.71 ± 0.70 logMAR units in the CNV group. At 2 years, the central foveal and PED thicknesses were not significantly different among the 3 groups, and the lesion was significantly larger in the PCV and CNV groups than in the avascular group.
CONCLUSIONS: The vascularized PED cases had a poorer visual outcome than avascular PEDs with anti-VEGF drugs at the 2-year follow-up.
Authors:
Takayuki Baba; Masayasu Kitahashi; Mariko Kubota-Taniai; Toshiyuki Oshitari; Shuichi Yamamoto
Related Documents :
6732578 - Treatment of xerophthalmia with retinol, tretinoin, and etretinate.
23204608 - Occurrence of epilepsy at different zeitgeber times alters sleep homeostasis differentl...
21838198 - Anti-oxidant treatment in obstructive sleep apnoea syndrome.
10872918 - Effect of sr121463, a selective non-peptide vasopressin v2 receptor antagonist, in a ra...
10488278 - Anesthesia considerations for patients with narcolepsy.
14592258 - Excessive fragmentary hypnic myoclonus: clinical and neurophysiological findings.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-04-13
Journal Detail:
Title:  Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde     Volume:  228     ISSN:  1423-0267     ISO Abbreviation:  Ophthalmologica     Publication Date:  2012  
Date Detail:
Created Date:  2012-07-31     Completed Date:  2012-10-05     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  0054655     Medline TA:  Ophthalmologica     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  102-9     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 S. Karger AG, Basel.
Affiliation:
Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, Japan. babatakayuki@nifty.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angiogenesis Inhibitors / administration & dosage
Antibodies, Monoclonal, Humanized / administration & dosage
Choroid / blood supply
Choroid Diseases / diagnosis,  drug therapy,  physiopathology
Choroidal Neovascularization / diagnosis,  drug therapy,  physiopathology
Female
Fluorescein Angiography
Follow-Up Studies
Fovea Centralis
Humans
Indocyanine Green / diagnostic use
Intravitreal Injections
Macular Degeneration / diagnosis,  drug therapy,  physiopathology*
Male
Polyps / diagnosis,  drug therapy,  physiopathology
Retinal Detachment / diagnosis,  drug therapy,  physiopathology*
Retinal Pigment Epithelium
Tomography, Optical Coherence
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Visual Acuity / physiology*
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 0/ranibizumab; 2S9ZZM9Q9V/bevacizumab; 3599-32-4/Indocyanine Green

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Conduit diameter and wall remodeling in elite athletes and spinal cord injury.
Next Document:  Is isoniazid for 6 months more cost-effective than isoniazid for 9 months?